Brokers Offer Predictions for Novartis AG’s FY2018 Earnings (NVS)

Novartis AG (NYSE:NVS) – Equities researchers at Jefferies Group lowered their FY2018 earnings per share estimates for Novartis AG in a research report issued on Friday. Jefferies Group analyst J. Holford now anticipates that the company will earn $5.25 per share for the year, down from their previous forecast of $5.32. Jefferies Group also issued estimates for Novartis AG’s FY2019 earnings at $6.10 EPS and FY2021 earnings at $7.68 EPS.

Novartis AG (NYSE:NVS) last posted its earnings results on Tuesday, April 25th. The company reported $1.13 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.10 by $0.03. The company had revenue of $11.54 billion for the quarter, compared to analyst estimates of $11.59 billion. Novartis AG had a net margin of 13.10% and a return on equity of 15.46%. The business’s revenue for the quarter was down .5% compared to the same quarter last year. During the same period last year, the business posted $1.17 earnings per share.

ILLEGAL ACTIVITY NOTICE: “Brokers Offer Predictions for Novartis AG’s FY2018 Earnings (NVS)” was originally posted by Stock Observer and is the property of of Stock Observer. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.thestockobserver.com/2017/06/20/brokers-offer-predictions-for-novartis-ags-fy2018-earnings-nvs.html.

Earnings History and Estimates for Novartis AG (NYSE:NVS)

A number of other research analysts also recently issued reports on NVS. Vetr upgraded shares of Novartis AG from a “hold” rating to a “buy” rating and set a $79.30 price target on the stock in a research report on Wednesday, March 1st. BNP Paribas downgraded shares of Novartis AG from a “neutral” rating to an “underperform” rating in a research report on Tuesday, March 7th. Societe Generale upgraded shares of Novartis AG from a “hold” rating to a “buy” rating and boosted their target price for the company from $73.82 to $74.37 in a research report on Tuesday, March 7th. Barclays PLC started coverage on shares of Novartis AG in a research report on Tuesday, March 7th. They set an “underweight” rating on the stock. Finally, Liberum Capital started coverage on shares of Novartis AG in a research report on Thursday, March 9th. They set a “buy” rating on the stock. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $83.12.

Novartis AG (NYSE NVS) traded up 0.80% during midday trading on Monday, reaching $82.09. 844,698 shares of the company’s stock traded hands. The firm has a market cap of $194.19 billion, a price-to-earnings ratio of 30.86 and a beta of 0.76. Novartis AG has a 1-year low of $66.93 and a 1-year high of $83.58. The stock’s 50 day moving average price is $80.28 and its 200 day moving average price is $75.35.

Several hedge funds have recently bought and sold shares of NVS. Causeway Capital Management LLC raised its stake in Novartis AG by 6.3% in the first quarter. Causeway Capital Management LLC now owns 338,149 shares of the company’s stock valued at $25,114,000 after buying an additional 20,131 shares during the last quarter. Laurel Wealth Advisors Inc. raised its stake in Novartis AG by 7.9% in the first quarter. Laurel Wealth Advisors Inc. now owns 18,553 shares of the company’s stock valued at $1,377,000 after buying an additional 1,352 shares during the last quarter. Columbia Partners L L C Investment Management raised its stake in Novartis AG by 12.1% in the first quarter. Columbia Partners L L C Investment Management now owns 15,200 shares of the company’s stock valued at $1,128,000 after buying an additional 1,640 shares during the last quarter. Franklin Parlapiano Turner & Welch LLC purchased a new stake in Novartis AG during the first quarter valued at about $3,428,000. Finally, Sowell Financial Services LLC raised its stake in Novartis AG by 118.6% in the first quarter. Sowell Financial Services LLC now owns 3,358 shares of the company’s stock valued at $273,000 after buying an additional 1,822 shares during the last quarter. Hedge funds and other institutional investors own 11.37% of the company’s stock.

Novartis AG Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply